Mon, October 3, 2022
Sun, October 2, 2022
Fri, September 30, 2022
Thu, September 29, 2022
Wed, September 28, 2022
Tue, September 27, 2022
Mon, September 26, 2022
Fri, September 23, 2022
Thu, September 22, 2022
Wed, September 21, 2022
Tue, September 20, 2022

Vikram Purohit Maintained (ARQT) at Buy with Increased Target to $46 on, Sep 27th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-46-on-sep-27th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Vikram Purohit of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Increased Target from $45 to $46 on, Sep 27th, 2022.

Vikram has made no other calls on ARQT in the last 4 months.



There are 4 other peers that have a rating on ARQT. Out of the 4 peers that are also analyzing ARQT, 0 agree with Vikram's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Vikram


  • Sean Kim of "JonesTrading" Initiated at Strong Buy and Held Target at $54 on, Thursday, September 22nd, 2022
  • Serge Belanger of "Needham" Initiated at Strong Buy and Held Target at $46 on, Wednesday, September 7th, 2022
  • Jonathan Block of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $50 on, Tuesday, August 2nd, 2022
  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Increased Target to $39 on, Tuesday, June 7th, 2022

Publication Contributing Sources